SURMOUNT Trial Program — Pivotal Tirzepatide Weight-Loss Studies

Detail

SURMOUNT-1 (Jastreboff AM, NEJM 2022, n=2,539, PMID 35658024) demonstrated 22.5% mean weight loss at 15 mg over 72 weeks in adults without diabetes. SURMOUNT-2 (Garvey WT, Lancet 2023) confirmed efficacy in T2D patients. SURMOUNT-3 (Wadden TA, Nat Med 2023) added intensive lifestyle intervention. SURMOUNT-4 (Aronne LJ, JAMA 2024) studied maintenance after initial weight loss.

Sources

This page references peer-reviewed publications listed on PubMed and FDA prescribing information labels. Methodology for source selection is documented on the Methodology page.